Article PDF first page preview

First page of Analysis of Brain Functional Connectivity in Patients with Delayed Encephalopathy After Carbon Monoxide Poisoning Based on Functional Near-Infrared Spectroscopy Technology

Objective: To observe the brain network characteristics of delayed encephalopathy after carbon monoxide poisoning (DEACMP) using functional near-infrared spectroscopy (fNIRS) technology. Methods: Fifteen patients with Carbon monoxide (CO) poisoning (DEACMP group) hospitalized in the Department of Neurology, Affiliated Hospital of North Sichuan Medical College, from November 2023 to March 2024 were selected. Fifteen healthy volunteers (the control group) were also recruited. Six-minute resting-state fNIRS data were collected from all subjects. Five cognitive-related key brain regions were selected as regions of interest (ROI): parietal cortex (PC), premotor cortex (PMC), frontopolar cortex (FPC), orbitofrontal cortex (OFC), and dorsolateral prefrontal cortex (DLPFC). NirSpark software was used to analyze the differences in whole-brain functional connectivity strength and functional connectivity strength within and between ROIs between the two groups. Results:The functional connectivity strength of the left PMC, right PMC, and left FPC ,etc.In the DEACMP group was significantly lower than that in the control group (P<0.05, FDR corrected). Compared with the control group, the brain network of DEACMP patients showed heterogeneity from left PC to right PC; Left PC~Left PMC; Left PC~right PMC; Left PC~Left DLPFC ,etc.The functional connectivity strength between the left PC and the right DLPFC area has significantly decreased. All these differences were statistically significant (P<0.05, FDR adjusted). Conclusion: DEACMP exhibits abnormal functional connectivity in both whole-brain and cognitive-related key brain regions. This aberrant connectivity may represent the underlying neural network mechanisms responsible for the cognitive dysfunction observed in DEACMP.

Journal Section:
Clinical Neurology
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.